Clin2
NCT05312255Possibly a fitRecruiting

Non-drug help to improve quality of life in myeloma

Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaSmoldering Plasma Cell Myeloma

Treatments studied

Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.

This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
175 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older
  • You must have good or moderate ability to do daily activities (ECOG score 0–2, depending on the group)
  • You must fit one of the study groups based on your diagnosis: smoldering myeloma, multiple myeloma/plasma cell leukemia, or for another group low-risk MDS that doesn’t need transfusions
  • You must be able to understand and follow study steps, and you must sign consent before any study procedures
  • You must not have major health problems that make the study unsafe, and your doctor must think it’s safe for you to participate
  • For some groups, you need internet access on a device with camera/mic/speakers, and for the beta-blocker group you must be newly diagnosed and not started on whole-body (systemic) treatment yet

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma

This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.

Houston, Texas
NCT05561387Recruiting· Phase 3
Drug combinations for newly diagnosed myeloma without transplant

This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.

Anchorage, Alaska
NCT07236502Recruiting
Moving forward with myeloma: Exercise and lifestyle program

This study tests a lifestyle program with exercise and nutrition guidance for people who have had multiple myeloma for at least one year. The goal is to see if it helps improve daily wellbeing and strength.

Maywood, Illinois
NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy

This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.

Seocho, Seoul
NCT07547007Recruiting
Exercise Program to Improve Life Quality After Myeloma Treatment

This study tests whether a 6-month personalized exercise program—done partly at home and partly at a center—can improve quality of life for patients with multiple myeloma (a blood cancer) who are receiving ongoing chemotherapy or targeted drugs. The program is tailored to your abilities and fits into your regular hospital visits.

Annecy
NCT07226609Recruiting
Plant-based diet study for multiple myeloma patients

This study tests if a plant-based diet can help people with newly diagnosed multiple myeloma who are receiving a standard 4-cycle drug combination (DRVd). Researchers want to see if changing what you eat might improve treatment results.

Basking Ridge, New Jersey

Hear when a new Plasma Cell Myeloma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.